IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
2007 NOV 19 -- IDM Pharma, Inc. (NASDAQ:IDMI) announced updated results from a Phase 2 UVIDEM(R) (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The updated results showed that the investigational agent UVIDEM showed evidence of clinical activity and induction of immune response and was well tolerated in patients with advanced melanoma. The data are being presented during a poster session at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting today in Boston. "There is a distinct need in the medical community for new treatments for metastatic melanoma," said Dr. Antoni Ribas, associate professor of medicine and surgery at UCLA and associate director of tumor immunology at the Jonsson Comprehensive Cancer Center. "The early analysis of data from the Phase 2 clinical trial with IDM Pharma's cancer vaccine, UVIDEM, has demonstrated that a small portion of patients is able to gain control of their disease through stimulating their bodies' natural defenses -- their immune system cells, and they were able to do so with minimal side effects." Keywords: Biological Therapy, Biotechnology, Biotherapy, Cancer Vaccines, Clinical Trial Research, IDM Pharma, Immunization, Melanoma, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Treatment, Vaccination, IDM Pharma Inc. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
